PDF(Sci-hub)
Abstract：
Clear-cell renal cell carcinoma (ccRCC) is one of the most common malignancies in humans and is usually associated with poor outcomes. Cancers are considered to be genetic diseases. Therefore, a better understanding of genetic alterations that are related to disease progression or poor prognosis can help to more precisely identify high-risk patients and treat them more effectively. The aim of this study was to examine the frequency of whole chromosome 9 loss (monosomy of chromosome 9) and its prognostic value in patients with ccRCC.
Single nucleotide polymorphism-based chromosome microarray (CMA) analysis was performed on 103 resected specimens from patients with ccRCC who had undergone partial or radical nephrectomy between January 2002 and March 2017 at Fox Chase Cancer Center. Monosomy 9 was correlated with clinicopathologic parameters and recurrence-free survival.
Chromosome 9 loss was detected in 31 (30%) of 103 tumors. Tumors with chromosome 9 loss had higher histologic grade (3 and 4; P < .001) and pathologic stage (P < .001). In 59 patients with non-metastatic ccRCC, chromosome 9 loss was also associated with higher recurrence rate and shorter recurrence-free survival (RFS) (12-month RFS, 77.8%; 95% confidence interval, 36.5%-93.9% for chromosome 9 loss vs. 95.7%; 95% confidence interval, 84.0%-98.9% for no loss; P = .002).
Chromosome 9 loss was found in 30% of patients with ccRCC and correlated with higher grade, advanced stage, and shorter RFS in patients with Stage I to III ccRCC.
Single nucleotide polymorphism-based chromosome microarray (CMA) analysis was performed on 103 resected specimens from patients with ccRCC who had undergone partial or radical nephrectomy between January 2002 and March 2017 at Fox Chase Cancer Center. Monosomy 9 was correlated with clinicopathologic parameters and recurrence-free survival.
Chromosome 9 loss was detected in 31 (30%) of 103 tumors. Tumors with chromosome 9 loss had higher histologic grade (3 and 4; P < .001) and pathologic stage (P < .001). In 59 patients with non-metastatic ccRCC, chromosome 9 loss was also associated with higher recurrence rate and shorter recurrence-free survival (RFS) (12-month RFS, 77.8%; 95% confidence interval, 36.5%-93.9% for chromosome 9 loss vs. 95.7%; 95% confidence interval, 84.0%-98.9% for no loss; P = .002).
Chromosome 9 loss was found in 30% of patients with ccRCC and correlated with higher grade, advanced stage, and shorter RFS in patients with Stage I to III ccRCC.
摘要：
透明细胞肾细胞癌（ccRCC）是人类最常见的恶性肿瘤之一，通常与不良预后相关。癌症被认为是遗传性疾病。因此,更好地了解与疾病进展或不良预后相关的基因改变有助于更准确地识别高危患者并更有效地治疗.这项研究的目的是检查ccRCC患者9号染色体全丢失（9号染色体单体性）的频率及其预后价值。
对2002年1月至2017年3月在FoxChase癌症中心接受部分或根治性肾切除术的ccRCC患者的103例切除标本进行了基于单核苷酸多态性的染色体微阵列（CMA）分析。9组与临床病理参数和无复发生存率相关。
在103个肿瘤中的31个(30%)中检测到9号染色体丢失。9号染色体缺失的肿瘤具有较高的组织学分级（3和4；P<.001）和病理分期（P<.001）。在59例非转移性ccRCC患者中，9号染色体缺失也与较高的复发率和较短的无复发生存期（RFS）（12个月RFS，77.8%；95%置信区间，36.5％-93.9％的9号染色体丢失与95.7%；95%置信区间，84.0%-98.9%，无损失；P=0.002）。
在30％的ccRCC患者中发现9号染色体丢失，并且与更高的分级相关。高级阶段,I至III期ccRCC患者的RFS较短。
对2002年1月至2017年3月在FoxChase癌症中心接受部分或根治性肾切除术的ccRCC患者的103例切除标本进行了基于单核苷酸多态性的染色体微阵列（CMA）分析。9组与临床病理参数和无复发生存率相关。
在103个肿瘤中的31个(30%)中检测到9号染色体丢失。9号染色体缺失的肿瘤具有较高的组织学分级（3和4；P<.001）和病理分期（P<.001）。在59例非转移性ccRCC患者中，9号染色体缺失也与较高的复发率和较短的无复发生存期（RFS）（12个月RFS，77.8%；95%置信区间，36.5％-93.9％的9号染色体丢失与95.7%；95%置信区间，84.0%-98.9%，无损失；P=0.002）。
在30％的ccRCC患者中发现9号染色体丢失，并且与更高的分级相关。高级阶段,I至III期ccRCC患者的RFS较短。
